Lupin logo

LUPIN - Lupin News Story

₹1178.45 -33.8  -2.8%

Last Trade - 14/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £5.18bn
Enterprise Value £5.26bn
Revenue £1.47bn
Position in Universe 82nd / 3111

BUZZ-India's GlaxoSmithKline Pharma falls 3% after heartburn drug recall

Thu 26th September, 2019 5:47am
** India's GlaxoSmithKline Pharmaceuticals Ltd  GLAX.NS 
falls as much as 3.8% to 1,382.20 rupees, marking its biggest
intraday percentage drop in over 10 weeks
    ** GSK Pharma said on Wednesday it suspended the release,
distribution and supply of all dose forms of ranitidine
hydrochloride products, a drug used to treat stomach ulcers, to
all markets  urn:newsml:reuters.com:*:nFWN26G05C
    ** The Indian arm of Britain's largest drugmaker is also
recalling zinetac tablets after the U.S. and European health
regulators said earlier this month they were reviewing the
safety of ranitidine 
    ** Regulators said some ranitidine medicines contain
carcinogens at low levels 
    ** Earlier this week, drug maker Dr.Reddy's Laboratories Ltd
 REDY.NS  said it was suspending global distribution of
ranitidine and several global pharmaceutical companies have
started recalling the heartburn drug  urn:newsml:reuters.com:*:nL3N26G45R
    ** Lupin Ltd  LUPN.NS  trades little changed, Sun
Pharmaceutical Industries Ltd  SUN.NS  gains 0.8% and Reddy's
Laboratories falls 0.1% 
    
    

 (Sethuraman.NR@thomsonreuters.com; 91 8067496031)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.